There are two basic techniques to combine chemotherapeutic agent toxicity and the precise targeting of EGFR overexpressing tumor tissues: antibody–drug conjugates (ADCs) and antibody–nanoparticle conjugates (ANCs). The gene discussed is EGFR; the disease is neoplasm.